107 related articles for article (PubMed ID: 36594508)
21. Effective Reduction of SARS-CoV-2 RNA Levels Using a Tailor-Made Oligonucleotide-Based RNA Inhibitor.
Nemethova V; Mazancova P; Selc M; Jakic K; Uhelska L; Nemethova B; Poturnayova A; Drgona L; Babelova A; Razga F
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458415
[TBL] [Abstract][Full Text] [Related]
22. Characterization of SARS-CoV-2 replication complex elongation and proofreading activity.
Jones AN; Mourão A; Czarna A; Matsuda A; Fino R; Pyrc K; Sattler M; Popowicz GM
Sci Rep; 2022 Jun; 12(1):9593. PubMed ID: 35688849
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis.
Guo S; Lei X; Chang Y; Zhao J; Wang J; Dong X; Liu Q; Zhang Z; Wang L; Yi D; Ma L; Li Q; Zhang Y; Ding J; Liang C; Li X; Guo F; Wang J; Cen S
Signal Transduct Target Ther; 2022 Dec; 7(1):400. PubMed ID: 36575184
[TBL] [Abstract][Full Text] [Related]
24. Identification and characterization of mutations in the SARS-CoV-2 RNA-dependent RNA polymerase as a promising antiviral therapeutic target.
Yashvardhini N; Jha DK; Bhattacharya S
Arch Microbiol; 2021 Nov; 203(9):5463-5473. PubMed ID: 34410443
[TBL] [Abstract][Full Text] [Related]
25. Surface plasmon resonance approach to study drug interactions with SARS-CoV-2 RNA-dependent RNA polymerase highlights treatment potential of suramin.
Mravinec M; Bajc G; Butala M
J Virol Methods; 2021 Dec; 298():114283. PubMed ID: 34534610
[TBL] [Abstract][Full Text] [Related]
26. The SARS-unique domain (SUD) of SARS coronavirus contains two macrodomains that bind G-quadruplexes.
Tan J; Vonrhein C; Smart OS; Bricogne G; Bollati M; Kusov Y; Hansen G; Mesters JR; Schmidt CL; Hilgenfeld R
PLoS Pathog; 2009 May; 5(5):e1000428. PubMed ID: 19436709
[TBL] [Abstract][Full Text] [Related]
27. Biostructural Models for the Binding of Nucleoside Analogs to SARS-CoV-2 RNA-Dependent RNA Polymerase.
Prussia AJ; Chennamadhavuni S
J Chem Inf Model; 2021 Mar; 61(3):1402-1411. PubMed ID: 33655751
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an
Elfiky AA
J Biomol Struct Dyn; 2021 Jun; 39(9):3204-3212. PubMed ID: 32338164
[TBL] [Abstract][Full Text] [Related]
29. Targeting Viral RNA-Dependent RNA Polymerases as an Antiviral Therapy.
Miranda D; Sanchez DJ
Curr Med Chem; 2021; 28(40):8384-8391. PubMed ID: 33563150
[TBL] [Abstract][Full Text] [Related]
30. Long-chain polyphosphates impair SARS-CoV-2 infection and replication.
Ferrucci V; Kong DY; Asadzadeh F; Marrone L; Boccia A; Siciliano R; Criscuolo G; Anastasio C; Quarantelli F; Comegna M; Pisano I; Passariello M; Iacobucci I; Monica RD; Izzo B; Cerino P; Fusco G; Viscardi M; Brandi S; Pierri BM; Borriello G; Tiberio C; Atripaldi L; Bianchi M; Paolella G; Capoluongo E; Castaldo G; Chiariotti L; Monti M; De Lorenzo C; Yun KS; Pascarella S; Cheong JH; Kim HY; Zollo M
Sci Signal; 2021 Jul; 14(690):. PubMed ID: 34230209
[TBL] [Abstract][Full Text] [Related]
31. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
Karthic A; Kesarwani V; Singh RK; Yadav PK; Chaturvedi N; Chauhan P; Yadav BS; Kushwaha SK
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164069
[TBL] [Abstract][Full Text] [Related]
32. Potential G-quadruplexes and i-Motifs in the SARS-CoV-2.
Belmonte-Reche E; Serrano-Chacón I; Gonzalez C; Gallo J; Bañobre-López M
PLoS One; 2021; 16(6):e0250654. PubMed ID: 34101725
[TBL] [Abstract][Full Text] [Related]
33. Cyanorona-20: The first potent anti-SARS-CoV-2 agent.
Rabie AM
Int Immunopharmacol; 2021 Sep; 98():107831. PubMed ID: 34247016
[TBL] [Abstract][Full Text] [Related]
34. A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp).
Ribaudo G; Ongaro A; Oselladore E; Zagotto G; Memo M; Gianoncelli A
J Biomol Struct Dyn; 2022 Feb; 40(3):1101-1108. PubMed ID: 32948103
[TBL] [Abstract][Full Text] [Related]
35. 5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis.
Zhao J; Liu Q; Yi D; Li Q; Guo S; Ma L; Zhang Y; Dong D; Guo F; Liu Z; Wei T; Li X; Cen S
Antiviral Res; 2022 Feb; 198():105254. PubMed ID: 35101534
[TBL] [Abstract][Full Text] [Related]
36. Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination.
Padhi AK; Dandapat J; Saudagar P; Uversky VN; Tripathi T
FEBS Lett; 2021 Sep; 595(18):2366-2382. PubMed ID: 34409597
[TBL] [Abstract][Full Text] [Related]
37. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
38. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
39. Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.
Konkolova E; Dejmek M; Hřebabecký H; Šála M; Böserle J; Nencka R; Boura E
Antiviral Res; 2020 Oct; 182():104899. PubMed ID: 32763313
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 RNA-Dependent RNA Polymerase Follows Asynchronous Translocation Pathway for Viral Transcription and Replication.
Wang X; Xu T; Yao Y; Cheung PP; Gao X; Zhang L
J Phys Chem Lett; 2023 Nov; 14(45):10119-10128. PubMed ID: 37922192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
